Cisplatin

Glavne informacije

  • Zaščiteno ime:
  • Cisplatin 1mg/ml Trockensubstanz Medac
  • Farmacevtska oblika:
  • Prašek za raztopino za infundiranje
  • Pot uporabe:
  • Način uporabe nedoločen
  • Enote v paketu:
  • škatla z 1 vialo s 1000 mg praška
  • Tip zastaranja:
  • / - Način/režim izdaje ni določen.
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • Cisplatin 1mg/ml Trockensubstanz Medac
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • cisplatin

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Zdravilo z začasnim dovoljenjem za vnos/uvoz za posamično zdravl
  • Datum dovoljenje:
  • 25-03-2011
  • Zadnja posodobitev:
  • 26-05-2018

18-5-2018

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Keytruda (pembrolizumab) or Tecentriq (atezolizumab): FDA Alerts Health Care Professionals and Investigators: FDA Statement - Decreased Survival in Some Patients in Clinical Trials Associated with Monotherapy

Early reviews found patients in the monotherapy arms of both trials with PD-L1 low status had decreased survival compared to patients who received cisplatin- or carboplatin-based chemotherapy.

FDA - U.S. Food and Drug Administration

Ni novosti v zvezi s tem izdelkom